Short communication: genetic variations of SLC2A9 in relation to Parkinson’s disease
1 Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
2 Molecular Genetics Core Facility, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
3 Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
Translational Neurodegeneration 2013, 2:5 doi:10.1186/2047-9158-2-5Published: 19 February 2013
Epidemiological studies showed that higher plasma urate was associated with lower risk for Parkinson’s disease (PD) and slower disease progression. Recent genome-wide association studies (GWAS) consistently showed that several single nucleotide polymorphisms (SNPs) in the solute carrier family 2 member 9 gene (SLC2A9 ) were associated with plasma urate concentration and the risk of gout.
We conducted a case–control study to examine twelve tag SNPs of the SLC2A9 gene in relation to PD among 788 cases and 911 controls of European ancestry. Odds ratios (OR) and 95% confidence intervals (CI) were derived from logistic regression models, adjusting for age, sex, smoking and caffeine consumption.
These SNPs were all in linkage disequilibrium (R2 > 0.7). None of them were associated with PD risk. Among women, however, there was a suggestion that the presence of the minor allele of one SNP (rs7442295) was related to a small increase in PD risk [OR (95% CI) = 1.48 (1.01-2.16)].
This study provides little support for genetic variations of SLC2A9 and PD risk.